pemetrexed · Actavis · NDA 208419, 215179
Pemetrexed
Earliest generic entry, as listed · earliest of 6 marketed strengths
26 Mar 2035
3 of 6 marketed strengths have no unexpired patent or exclusivity listed.
Blocked by patent: US 11147817.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11147817 | product | 26 Mar 2035 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208419 · 001 · RLD | solution, intravenous | 100MG/4ML (25MG/ML) | open |
| 208419 · 002 · RLD | solution, intravenous | 500MG/20ML (25MG/ML) | open |
| 208419 · 003 · RLD | solution, intravenous | 1GM/40ML (25MG/ML) | open |
| 215179 · 001 · RLD | solution, intravenous | EQ 100MG/10ML BASE (10MG/ML) | 26 Mar 2035 |
| 215179 · 002 · RLD | solution, intravenous | EQ 500MG/50ML BASE (10MG/ML) | 26 Mar 2035 |
| 215179 · 003 · RLD | solution, intravenous | EQ 1GM/100ML BASE (10MG/ML) | 26 Mar 2035 |